SHIFT Newsroom · GLOBAL
GLP-1 medicines and arthritis: reviewing mixed evidence
This review brings together evidence on GLP-1 receptor agonists in osteoarthritis and inflammatory arthritis. The evidence varies by condition and study design. It is not a new trial demonstrating an established benefit for all forms of arthritis.
What the source says
This review brings together evidence on GLP-1 receptor agonists in osteoarthritis and inflammatory arthritis. The evidence varies by condition and study design. It is not a new trial demonstrating an established benefit for all forms of arthritis.
Evidence and limits
The review draws together laboratory research, trials and observational studies. It describes modest pain and function improvements in some knee-osteoarthritis trials, mixed observational findings and limited evidence in inflammatory arthritis. These are different evidence bases.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
Sore knees need practical movement choices as well as appropriate clinical help. This review does not promise that a weight-management medicine will treat your arthritis.
Known facts
- This review brings together evidence on GLP-1 receptor agonists in osteoarthritis and inflammatory arthritis.